Navigation Links
Former Senator Byron Dorgan Elected to Codexis Board
Date:2/17/2011

REDWOOD CITY, Calif., Feb. 17, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Byron Dorgan, former U.S. Senator from North Dakota, has been elected to the company's Board of Directors. Senator Dorgan retired from the Senate in January 2011 after a 30-year career in the U.S. Congress.  

(Photo:  http://photos.prnewswire.com/prnh/20110217/SF50619)

"We are very pleased to welcome Byron Dorgan to our Board," said Alan Shaw, Ph.D., President and Chief Executive Officer.  "He is a champion of new technologies to enable innovation and has long advocated energy security through a comprehensive national energy policy. As Chairman of the Senate Energy and Water Appropriations Subcommittee, he worked to fund broad development of renewable energy sources. His substantial expertise will be valuable to Codexis."

Senator Dorgan served in the Senate leadership for 16 years, first as Assistant Democratic Floor Leader and then as Chairman of the Democratic Policy Committee. He was Chairman of the Senate Committees and Subcommittees on the issues of Appropriations, Commerce, Energy, Aviation, Water Policy, and Indian Affairs. First elected to Congress in 1980, Dorgan served six terms in the U.S. House of Representatives and three terms in the U.S. Senate. He was also North Dakota's youngest-ever constitutional officer when he was appointed State Tax Commissioner.

While in Congress, he built a reputation as a forward-looking energy policy maker, supporting the use of renewable energy and domestic energy sources, and moving away from a reliance on foreign oil.  He also emerged as one of the nation's leading voices on behalf of America's agriculture industry. He worked to expand North Dakota's burgeoning energy sector, preserve a strong safety net for family farmers, and spur economic development.

Senator Dorgan earned his Bachelor of Science degree from the University of North Dakota and his Master of Business Administration from the University of Denver.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Robert Lawson, robert.lawson@codexis.com, 650-421-8137


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Former Speaker of the House Newt Gingrich Featured Wednesday
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Former Cables to Go/Lastar Inc. Employee's Move to Form American Consumer Cables Pays Off
4. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
5. Former Telomolecular CEO Clarifies SEC Settlement
6. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
7. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 A Europe-wide survey of ... researchers using animals in their research treat them with due care. ... and detailed analysis of the results indicates that there is a ... to put into practice the principles of the 3Rs (Refine, ... What ...
(Date:2/27/2017)... Feb. 27, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the U.S. Food and Drug Administration (FDA) has ... section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual ... with moderate-to-severe acute pain in a medically supervised ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):